Pharmacovigilance and Regulatory Affairs

About Us

Welcome to the 4th International Forum on Pharmacovigilance and Regulatory Affairs, taking place on November 24–25, 2025, in the vibrant city of Barcelona, Spain. This highly anticipated event serves as a premier global platform dedicated to promoting dialogue, collaboration, and innovation in the field of drug safety, risk management, and regulatory science.

With the theme “Integrating Pharmacovigilance Across the Drug Lifecycle: From R&D to Post-Marketing,” the forum brings together top experts, industry leaders, regulatory authorities, healthcare professionals, researchers, and academics to discuss the latest trends, tools, and technologies shaping the future of pharmacovigilance and regulatory frameworks. We aim to create a collaborative space where regulatory professionals, pharmacovigilance officers, medical affairs experts, drug safety scientists, quality assurance teams, CROs, pharmacologists, and healthcare policymakers can exchange ideas, share case studies, and explore regulatory updates from agencies such as the EMA, FDA, MHRA, and WHO.

Call for Abstracts

Researchers, practitioners, and innovators are invited to submit abstracts for oral or poster presentations aligned with the forum’s core themes. Abstract submissions are open in three rounds:

First Round Deadline: July 30, 2025
Second Round Deadline: September 30, 2025
Final Round Deadline: November 5, 2025

All accepted abstracts will be included in the official conference proceedings, and select submissions will be considered for keynote and spotlight sessions.

Whether you're an established professional or emerging researcher, the 4th International Forum on Pharmacovigilance and Regulatory Affairs offers a unique opportunity to stay at the forefront of drug safety and regulatory transformation while networking with global thought leaders in the field.

Join us in Barcelona, a city known for its innovation, culture, and connectivity - as we work together to shape safer, smarter, and more transparent pharmaceutical systems worldwide.

CPD/CME/CEU points

All registered participants of the 4th International Forum on Pharmacovigilance and Regulatory Affairs, taking place on November 24–25, 2025, in Barcelona, Spain, will be eligible to receive 15–20 Continuing Education Credits (CME/CEU/CPD) for their full participation across the two-day conference.

These credits are awarded in accordance with international continuing education standards and are a testament to the participant’s ongoing professional development.

CME (Continuing Medical Education) credits are widely accepted by physicians, pharmacologists, and regulatory specialists who require proof of educational advancement for maintaining medical or pharmaceutical licensure.

CEU (Continuing Education Units) serve as recognition for nurses, clinical researchers, and allied health professionals pursuing structured learning for competency renewal.

CPD (Continuing Professional Development) credits are applicable across multiple disciplines, providing formal evidence of knowledge enhancement and skills improvement relevant to pharmacovigilance, drug safety, and regulatory affairs.

Participants will receive an official certificate at the conclusion of the event, indicating the number of credits earned, which may be submitted to professional licensing bodies or institutions for accreditation purposes. Engaging with industry leaders, global regulatory experts, and peers at this forum not only advances your knowledge but also helps meet licensure and institutional requirements for continuous learning.

Join us in Barcelona for two impactful days of insights, networking, and certified professional growth in the rapidly evolving landscape of pharmacovigilance and regulatory affairs!

Sessions

AI-Driven Signal Detection and Data Mining

Artificial Intelligence (AI) is rapidly transforming the landscape of pharmacovigilance, offering novel tools for efficient signal detection and adverse event analysis. Traditional methods often struggle with the volume, complexity, and variability of safety data collected globally. AI algorithms, especially machine learning and natural language processing, allow for real-time scanning of structured and unstructured data across spontaneous reports, clinical trials, electronic health records, and social media platforms. These technologies enhance the early identification of safety signals, reduce manual workload, and improve the precision of assessments.

Moreover, AI-driven systems can dynamically learn from new patterns in data, adapting to emerging trends and refining predictions with increasing accuracy. However, regulatory alignment, data standardization, and algorithm transparency remain critical to ensuring these tools complement existing frameworks effectively. Balancing automation with human oversight is essential to maintain scientific integrity and accountability in signal detection processes. As adoption grows, collaboration between regulatory authorities, industry stakeholders, and technology providers will be vital to harness AI's full potential in pharmacovigilance.

Global Harmonization of Regulatory Frameworks

The globalization of pharmaceutical markets has emphasized the urgent need for harmonized regulatory frameworks in pharmacovigilance. Disparate national regulations often lead to redundancies, inefficiencies, and gaps in drug safety monitoring. Efforts by international bodies such as ICH, WHO, EMA, and FDA are fostering convergence by standardizing terminologies (e.g., MedDRA), processes (e.g., ICH E2E), and reporting formats (e.g., E2B). Harmonization enables faster information exchange, uniform risk assessment, and consistent post-marketing surveillance across jurisdictions. It also facilitates regulatory reliance and work-sharing models, particularly benefiting resource-limited countries. However, challenges persist in aligning legal, cultural, and technological aspects across regions. Bridging these differences requires ongoing dialogue, capacity-building, and shared digital infrastructures. Ultimately, harmonized frameworks improve patient safety, accelerate regulatory decisions, and reduce the burden on industry while ensuring consistent pharmacovigilance practices worldwide.

Risk Management Planning and Benefit-Risk Assessment

Effective risk management planning is central to ensuring drug safety throughout a product’s lifecycle. It involves identifying, characterizing, and minimizing potential risks while enhancing the benefits of therapies. A robust benefit-risk assessment integrates clinical trial data, real-world evidence, and epidemiological insights to guide regulatory decisions, labeling, and post-approval strategies. Modern risk management plans (RMPs) must adapt to complex treatment modalities and diverse patient populations. They increasingly rely on advanced analytics and predictive models to forecast adverse events and evaluate intervention effectiveness. Transparency, stakeholder engagement, and clear communication are critical to build trust in benefit-risk decisions. Regulatory bodies expect continuous updates to RMPs based on emerging safety data, making dynamic surveillance systems essential. By aligning risk mitigation with real-world outcomes, stakeholders can ensure responsible use of medicines and enhance patient protection.

Pharmacovigilance in Accelerated Drug Approvals

Accelerated drug approval pathways, such as Fast Track, Breakthrough Therapy, and Conditional Approvals, enable timely access to life-saving treatments. However, these expedited processes often involve limited pre-market safety data, increasing the importance of robust pharmacovigilance mechanisms post-approval. Real-time surveillance, adaptive risk management, and active safety signal monitoring are critical to managing uncertainties around benefit-risk profiles. Innovative post-authorization safety studies (PASS), patient registries, and digital monitoring tools help close data gaps and inform risk mitigation strategies. Regulatory agencies demand proactive and transparent pharmacovigilance commitments from sponsors, including early signal detection, frequent reporting, and flexible response systems. Ensuring the safety of accelerated therapies requires a well-coordinated ecosystem of regulators, manufacturers, and healthcare professionals, underpinned by agile and resilient pharmacovigilance operations.

Real-World Evidence in Post-Marketing Surveillance

Real-world evidence (RWE) derived from sources such as electronic health records, insurance claims, registries, and patient-reported outcomes is playing an increasingly vital role in pharmacovigilance. Unlike controlled clinical trials, real-world data captures diverse patient experiences, comorbidities, and medication use patterns, offering a broader view of a product’s safety profile. RWE enhances post-marketing surveillance by enabling earlier signal detection, assessing long-term outcomes, and supporting regulatory decision-making. Its use is especially valuable for evaluating safety in underrepresented populations and rare adverse events. However, challenges remain around data quality, standardization, privacy, and integration across systems. Collaborative frameworks and advanced analytics are key to unlocking the full potential of RWE. As regulatory agencies expand their acceptance of RWE, its role in shaping post-marketing safety strategies will continue to grow significantly.

Digital Transformation in Drug Safety Operations

Digital transformation is reshaping pharmacovigilance by modernizing drug safety operations through advanced technologies and data-driven approaches. The shift from traditional manual workflows to digital ecosystems has enabled more agile, efficient, and responsive pharmacovigilance systems. Cloud computing, real-time analytics, electronic reporting tools, and integrated safety databases are enhancing data collection, signal detection, and regulatory submissions. This evolution supports seamless data exchange among sponsors, regulators, healthcare providers, and patients, leading to quicker identification and resolution of safety issues. Integration with electronic health records and global safety networks improves the quality and scope of post-marketing surveillance. Digital platforms also enhance case processing accuracy and reduce redundancy, allowing safety teams to focus on risk assessment and decision-making.

However, successful digital transformation requires careful planning, cross-functional collaboration, strong data governance, and adherence to evolving regulatory standards. It also demands a shift in culture and capabilities to embrace new technologies without compromising compliance or patient trust. As digitalization accelerates, organizations must balance innovation with regulatory robustness to deliver more transparent, effective, and scalable pharmacovigilance systems.

Blockchain Applications in Regulatory Data Integrity

Blockchain technology offers a groundbreaking approach to enhancing transparency, security, and trust in regulatory and pharmacovigilance data. By providing a decentralized, immutable ledger of transactions, blockchain ensures that every data point whether related to adverse events, clinical trial results, or regulatory filings is securely recorded, time-stamped, and traceable. This technology can significantly reduce data manipulation risks, facilitate faster audits, and improve regulatory compliance across the pharmaceutical value chain. In pharmacovigilance, blockchain enables real-time sharing of safety data among stakeholders, ensuring consistency and reducing duplication. It enhances the traceability of drug batches, linking adverse events with specific manufacturing lots or supply chains especially vital in biologics, vaccines, and personalized therapies.

Implementing blockchain also supports patient data ownership and consent tracking, ensuring ethical data usage. Despite its potential, challenges like interoperability, scalability, regulatory acceptance, and integration with legacy systems must be addressed. Continued collaboration between regulators, industry, and technology developers will be essential to unlocking blockchain’s full capabilities in ensuring data integrity and accountability in drug safety systems.

Patient-Centric Pharmacovigilance Strategies

Modern pharmacovigilance is evolving toward a more patient-centric approach, recognizing patients not only as recipients of care but as active contributors to drug safety. Empowering patients to report adverse events directly, engage with safety data, and participate in safety evaluations leads to more comprehensive and accurate pharmacovigilance systems. Digital health platforms, mobile apps, and online communities are transforming how patients share their experiences with medications. These tools enable real-time reporting, contextual insights, and early detection of signals that might be missed through traditional channels. Patient-reported outcomes also offer valuable information on the tolerability and real-world effects of therapies.

Implementing a patient-centric model requires tailored communication strategies, cultural sensitivity, and simplified reporting mechanisms to encourage participation. It also demands strong data protection and ethical frameworks to maintain trust. Integrating patient input into safety signal management, risk assessment, and regulatory decisions enhances transparency and accountability. As regulatory authorities increasingly emphasize patient engagement, patient-centric pharmacovigilance is becoming a cornerstone of modern drug safety practices.

Pharmacovigilance Compliance in Clinical Trials

Pharmacovigilance in clinical trials plays a critical role in ensuring the safety of participants and maintaining regulatory compliance throughout drug development. Regulatory agencies mandate robust safety oversight during trials, requiring timely reporting of adverse events, serious adverse events (SAEs), and suspected unexpected serious adverse reactions (SUSARs). Sponsors must implement risk-based monitoring, standardized case reporting, and transparent communication with investigators and ethics committees. The use of electronic data capture systems, centralized monitoring, and automated alerts strengthens early signal detection and supports regulatory obligations. Collaboration between clinical operations, medical monitors, and safety teams ensures accurate causality assessments and adherence to protocol requirements.

Maintaining compliance involves detailed documentation, proper training, and alignment with ICH-GCP, FDA, and EMA standards. Non-compliance can result in trial delays, regulatory penalties, or compromised data integrity. With the growing complexity of clinical studies, especially in oncology, rare diseases, and personalized medicine, pharmacovigilance in trials must be proactive, integrated, and responsive to emerging risks. Effective clinical trial safety oversight sets the foundation for a therapy’s long-term benefit-risk evaluation.

Automation in Case Processing and Reporting

Automation is revolutionizing pharmacovigilance case processing by streamlining repetitive tasks and accelerating the management of large volumes of safety data. Tools such as robotic process automation (RPA), natural language processing (NLP), and machine learning algorithms are reducing manual workload, increasing efficiency, and minimizing human error. These technologies enable faster data intake, triage, coding, narrative generation, and regulatory submission of individual case safety reports (ICSRs). By automating routine processes, safety professionals can focus on complex tasks like medical evaluation, signal detection, and benefit-risk analysis. Additionally, automation supports real-time compliance tracking and audit readiness, critical for meeting global regulatory timelines.

Despite its advantages, implementing automation requires careful validation, robust quality control, and alignment with pharmacovigilance regulations such as GVP and 21 CFR Part 11. It also necessitates change management and skill development among safety teams. When strategically adopted, automation not only enhances operational scalability but also strengthens the overall pharmacovigilance ecosystem.

Safety Monitoring of Biologics and Biosimilars

Biologics and biosimilars present unique challenges in pharmacovigilance due to their complex structures, manufacturing variability, and immunogenic potential. Unlike small-molecule drugs, biologics can induce immune responses that vary by patient population and product handling, making continuous safety monitoring essential. Post-marketing surveillance for biologics must address issues such as traceability, batch-specific effects, and rare but serious adverse events. Pharmacovigilance systems must distinguish between innovator biologics and biosimilars, especially when multiple products share the same active ingredient but differ in structure or formulation. This requires enhanced pharmacovigilance coding, product identification strategies, and comprehensive patient follow-up.

In biosimilars, regulatory expectations include comparative safety assessments with reference products and robust risk management plans. Stakeholder education is vital to ensure appropriate reporting and understanding of interchangeability. Collaboration between regulators, manufacturers, and healthcare providers plays a key role in building trust in biosimilars while safeguarding public health. As biologics dominate the pharmaceutical pipeline, their safety oversight demands tailored and scientifically rigorous pharmacovigilance strategies.

Pharmacovigilance in Gene and Cell Therapies

Gene and cell therapies represent a revolutionary class of treatments with curative potential, yet they come with complex and evolving safety profiles. These products often involve novel vectors, long-term biological activity, and individualized treatment regimens, making their risk assessment fundamentally different from conventional pharmaceuticals. Adverse events may be delayed, unpredictable, and patient-specific, requiring lifelong follow-up and innovative pharmacovigilance strategies. Pharmacovigilance systems must accommodate unique product attributes, such as persistence of genetic material, immune system activation, and off-target effects. Specialized registries, digital tracking tools, and long-term cohort studies are essential to monitor patient outcomes over extended periods. Regulatory expectations include comprehensive Risk Management Plans (RMPs) and proactive signal detection mechanisms, tailored to address the inherent uncertainties in these therapies. The integration of clinical insights, genomics, and patient-reported data enhances the ability to identify emerging risks. Collaboration among manufacturers, clinicians, and regulatory bodies ensures that the safety of gene and cell therapies is closely monitored while supporting innovation. As these therapies become more common, their pharmacovigilance frameworks must remain adaptive and scientifically rigorous.

Inspection Readiness and Audit Best Practices

Maintaining inspection readiness is critical for compliance and operational integrity in pharmacovigilance systems. Regulatory authorities such as the EMA, FDA, and MHRA routinely conduct audits and inspections to verify adherence to Good Pharmacovigilance Practices (GVP), data integrity, and global reporting obligations. Being audit-ready at all times requires well-documented processes, consistent quality controls, and a culture of proactive compliance. Effective audit preparedness begins with clear SOPs, real-time tracking systems, and ongoing internal audits that identify gaps before regulatory scrutiny. Training staff in compliance awareness, understanding audit scopes, and maintaining version-controlled documentation are essential for demonstrating due diligence. Cross-functional collaboration with clinical, quality, and IT teams further strengthens readiness. Risk-based approaches help prioritize inspection focus areas, such as signal detection, case processing timelines, and database validation. Technology, including audit trail tracking and e-documentation, supports transparency and accountability. A successful inspection readiness strategy not only avoids penalties but also reinforces trust among stakeholders and regulators, fostering a resilient and compliant pharmacovigilance infrastructure.

Global Signal Management Systems and Standards

Signal management is a cornerstone of pharmacovigilance, enabling early detection and evaluation of potential safety risks. Globally, regulatory agencies require a structured, documented process for signal detection, validation, prioritization, assessment, and communication. As pharmacovigilance becomes more data-driven, standardized systems and tools are essential to support the volume and complexity of safety information. Global harmonization efforts, such as ICH E2E and GVP Module IX, provide a framework for consistent signal management across jurisdictions. Signal detection algorithms using statistical disproportionality, machine learning, and real-world evidence offer improved sensitivity and specificity. Tools like EVDAS (EudraVigilance Data Analysis System) and FAERS (FDA Adverse Event Reporting System) are key in centralized signal evaluation. Cross-border data sharing and collaborative platforms strengthen global pharmacovigilance by enabling real-time exchange of emerging safety information. Maintaining alignment with international standards ensures compliance and facilitates timely decision-making. By adopting advanced methodologies and standardized processes, organizations enhance their ability to identify risks early and protect public health.

Safety Labeling Changes and Regulatory Communication

Timely and accurate safety labeling changes are critical to informing healthcare professionals and patients about evolving drug risks. Pharmacovigilance teams play a vital role in continuously monitoring safety data and initiating updates to product information, including contraindications, warnings, adverse reactions, and usage instructions. Regulatory authorities require structured documentation and evidence to support labeling changes. The process involves signal detection, risk assessment, expert consultation, and preparation of regulatory submissions, such as variation applications or safety update reports. Harmonizing labeling across global markets presents an additional challenge due to varying regional requirements and timelines. Effective communication strategies ensure that updated safety information reaches stakeholders promptly. This includes updates to package inserts, electronic labeling systems, Dear Healthcare Provider (DHCP) letters, and direct-to-patient communications. Digital tools and pharmacovigilance databases further streamline dissemination and compliance monitoring. Proactive management of labeling changes not only fulfills regulatory obligations but also enhances patient safety and trust. A transparent and coordinated approach between safety, regulatory affairs, and commercial teams is essential to ensure consistent and compliant safety messaging.

Adverse Event Reporting through Mobile Health Tools

Mobile health (mHealth) technologies are revolutionizing adverse event (AE) reporting by enabling real-time, patient-driven data submission. Apps, SMS services, and wearable devices offer convenient, accessible platforms for capturing and transmitting AE information, particularly in remote or underserved regions. This digital shift enhances the timeliness, granularity, and volume of safety data collected across the product lifecycle. Patient-reported outcomes captured via mobile tools often provide richer context than traditional channels, including symptom severity, treatment adherence, and quality of life. Integration with electronic health records and centralized safety databases enables seamless data flow and analysis. Mobile interfaces also allow healthcare professionals to report AEs efficiently at the point of care. Ensuring data accuracy, privacy, and regulatory compliance remains crucial. Systems must align with global standards such as GVP, HIPAA, and GDPR. Additionally, user-friendly design and patient education are key to encouraging adoption. As digital health becomes embedded in pharmacovigilance, mobile tools will play a central role in democratizing drug safety reporting and enhancing signal detection capabilities.

Integration of PV with Quality and Regulatory Affairs

Integrating pharmacovigilance with quality management and regulatory affairs creates a cohesive ecosystem that supports comprehensive drug safety oversight. These disciplines often operate in parallel, yet their alignment is essential for lifecycle management, risk mitigation, and compliance continuity. Collaboration ensures that safety data informs regulatory submissions, label changes, and manufacturing practices in real time. Quality systems contribute by managing deviations, CAPAs (Corrective and Preventive Actions), and audits that intersect with pharmacovigilance processes. Simultaneously, regulatory affairs teams guide timely submissions of safety updates, PSURs, and risk communication materials in alignment with global guidelines.

A unified approach promotes data consistency, enhances decision-making, and minimizes compliance gaps. Shared platforms, cross-functional SOPs, and regular joint reviews foster synchronization and accountability. With increasing regulatory scrutiny and product complexity, integration supports end-to-end traceability and a robust safety culture across the organization.

Pharmacovigilance Outsourcing and Vendor Oversight

The increasing complexity of drug safety operations has led many pharmaceutical companies to outsource pharmacovigilance functions to specialized vendors, contract research organizations (CROs), and service providers. While outsourcing can reduce operational costs and increase scalability, it also introduces challenges in maintaining quality, compliance, and data integrity. Effective vendor oversight is therefore critical to ensure adherence to regulatory requirements and protect patient safety. Robust governance frameworks must define clear roles, responsibilities, and communication pathways between sponsors and vendors. This includes implementing risk-based qualification processes, detailed contractual agreements, and measurable service level indicators. Regular audits, performance reviews, and quality checks help ensure ongoing compliance with Good Pharmacovigilance Practices (GVP) and international regulatory standards. Data ownership, accountability, and transparency are fundamental concerns in outsourced models. Seamless data exchange and system interoperability must be maintained, especially when multiple vendors are involved across regions or functional areas. Sponsors must also be prepared to demonstrate full oversight during regulatory inspections. A successful outsourcing strategy balances operational efficiency with proactive monitoring, ensuring that safety reporting, case processing, and signal management remain timely, accurate, and compliant.

Managing Safety Data in Multi-Region Submissions

Submitting pharmacovigilance data across multiple regulatory jurisdictions presents both strategic and operational challenges. While globalization enables wider drug access, it also requires sponsors to navigate differing regulatory expectations, reporting timelines, and safety formats. Coordinating multi-region safety submissions demands harmonized processes, flexible data systems, and strong cross-functional collaboration. One of the primary challenges is adapting to variations in Individual Case Safety Report (ICSR) formats, periodic safety update requirements (e.g., PSURs, PBRERs), and signal evaluation criteria among authorities like the EMA, FDA, PMDA, and others. Maintaining consistency while ensuring regional compliance requires detailed knowledge of local regulations and up-to-date regulatory intelligence. Translation accuracy, medical terminology alignment (e.g., MedDRA), and formatting nuances further complicate submission readiness. Centralized safety databases and cloud-based pharmacovigilance platforms support streamlined data integration and faster dissemination of information. Real-time dashboards, automated validation checks, and audit trails help manage workload and reduce errors. Strategic planning, efficient data standardization, and alignment with global regulatory frameworks are essential to mitigate risks and ensure successful safety reporting across regions.

Ethics and Legal Challenges in Drug Safety Surveillance

Ethical and legal considerations are central to the responsible practice of pharmacovigilance. As the scope and granularity of safety surveillance increase, so does the need to protect patient rights, data privacy, and informed consent. Regulatory bodies worldwide enforce strict guidelines to ensure that pharmacovigilance activities comply with legal frameworks such as GDPR, HIPAA, and other national data protection laws. Patient data used in adverse event reporting, signal detection, and post-marketing studies must be collected, stored, and processed with strict confidentiality and transparency. Informed consent becomes especially relevant in the era of digital health tools, real-world evidence, and genetic therapies. Clear communication about how patient data will be used is essential for maintaining trust and ethical accountability. Legal risks also arise from delayed or incomplete reporting, inadequate documentation, and failure to act on identified safety signals. Litigation related to adverse outcomes can lead to reputational damage, financial penalties, and regulatory sanctions. Companies must establish comprehensive compliance programs, legal oversight, and ethical review processes to mitigate these risks. Navigating the intersection of ethics, law, and science requires a multidisciplinary approach, involving pharmacovigilance professionals, legal advisors, ethicists, and regulators. A transparent, proactive, and ethically grounded pharmacovigilance system not only protects patients but also upholds the credibility and integrity of public health efforts.

Market Analysis

The global pharmacovigilance and regulatory affairs landscape has experienced significant transformation over the last decade, driven by technological advancements, evolving drug safety regulations, and the increasing complexity of therapeutic products. As pharmaceutical and biotechnology industries expand their portfolios with innovative therapies such as biologics, biosimilars, gene therapies, and personalized medicine, the demand for robust and proactive pharmacovigilance systems has intensified. The 4th International Forum on Pharmacovigilance and Regulatory Affairs, scheduled for November 24–25, 2025, in Barcelona, Spain, aligns with the urgent need to foster dialogue, collaboration, and best practices in this dynamic sector. According to recent market research, the global pharmacovigilance market is projected to surpass USD 15 billion by 2028, growing at a CAGR of over 12%. This growth is largely attributed to the rising volume of adverse drug reaction (ADR) reports, stringent regulatory compliance requirements across geographies, and the increasing adoption of electronic health records and data analytics tools. Outsourcing pharmacovigilance operations to specialized service providers is also becoming a key trend, particularly among small- and mid-sized enterprises seeking cost-effective compliance solutions. Regulatory affairs, as a complementary domain, is witnessing parallel growth. The global regulatory affairs outsourcing market is expected to reach USD 19 billion by 2030. This reflects the growing pressure on life sciences companies to navigate diverse and evolving global regulations while accelerating product approvals. Regulatory authorities such as the FDA, EMA, PMDA, and CDSCO have been continuously updating safety reporting frameworks, necessitating constant adaptation by industry players. The increased emphasis on post-marketing surveillance, real-world data integration, and risk management planning further fuels the demand for skilled regulatory professionals and cutting-edge technologies.

Artificial intelligence, machine learning, and automation are reshaping how pharmacovigilance activities are conducted. From intelligent signal detection and case processing to AI-powered literature monitoring and predictive analytics, digital transformation is unlocking new efficiencies and insights in drug safety. Simultaneously, patient-centric approaches are gaining momentum, with emphasis on incorporating patient-reported outcomes and improving transparency in safety communication. Blockchain is also emerging as a tool to ensure data integrity and traceability in regulatory documentation.

Past Conference Report

Euro Pharmacovigilance 2022

We warmly welcome all the participants to attend our event Euro Pharmacovigilance Meet 2022 entitled “3rd European Conference on Pharmacovigilance and Drug Safety” webinar scheduled on June 07-08, 2022,Webinar. Across the theme “COVID-19 Challenges for Pharmacovigilance and Drug Safety “

This conference provides a forum for interaction among attendees with discussion involving discovery of a new drug, Challenges in drug development. Which includes a large range of prompt Keynote presentations, Poster presentations, Oral presentation, Exhibitions, Symposiums & Workshops? It's a right platform for researchers, scientists and delegates to share their expertise, poster collaborations across business and domain, and valuate rising technologies across the globe.

Euro Pharmacovigilance 2022 Meet your target audience with members from around the world focused on learning about Pharmacovigilance and Drug Safety , this is your single best opportunity to reach the largest assemblage of participants from the Pharma and medicinal community, Find out how innovators are closing the gap between product development and adoption, Better identify cyber threats and reduce information security risks, Debate the potential to greater cross-industry and cross-sector collaboration in the race for faster, cheaper, better cures. Conduct demonstrations, distribute information, meet with current and potential Scientists, make a splash with a new research, and receive name recognition at this event Euro Pharmacovigilance 2022. World-renowned speakers, the most recent techniques, tactics, and the newest updates in Pharmaceutical Sciences fields are hallmarks of this conference.